New microtubular agents in pediatric oncology.
The taxanes are a new group of anticancer agents with a novel mechanism of action. They promote microtubule assembly and stabilize the microtubules. Paclitaxel (Taxol), the first agent in this group in clinical trials was isolated from the Pacific yew, Taxus brevifolia in 1971. Both in preclinical and clinical studies, paclitaxel and its semisynthetic analog docetaxel exhibit significant antitumor activity. This review will provide an overview of the clinical experience with the group of anti-microtubular agents, the taxanes in pediatric oncology.
Seibel
N L
NL
Department of Hematology/Oncology, Children's National Medical Center, Washington, D.C, USA.
Reaman
G H
GH
D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008870:Microtubules / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane